(Corrects fourth paragraph to say Grastek, not Ragwitek, will
compete with Stallergenes' drug)
April 17 The U.S. Food and Drug Administration
has approved Merck & Co's pollen allergy drug Ragwitek.
The tablet, which is administered by placing it under the
tongue, is to treat the short ragweed pollen induced allergic
The approval for Ragwitek comes days after U.S. regulatory
approval for Merck's grass pollen allergy drug Grastek.
Merck's Grastek will compete with Stallergenes SA's
immunotherapy treatment for five types of grass
pollen, which was approved by the FDA earlier this month.
(Reporting by Shailesh Kuber; Editing by Sriraj Kalluvila)